A phase 2 study of bortezomib in relapsed, refractory myeloma.

By P. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, S. Rajkumar, G. Srkalović, M. Alsina, R. Alexanian and 11 more. New England Journal of Medicine, 2003

2,697 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/34ebdac24e9d1f623de3971f6b1e11dca6d89635

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. S. Rajkumar
2. J. Adams
3. Christopher M. Overall

In Molecular Biology

1. S. Rajkumar
2. J. Adams
3. Masakazu Toi
4. Chikashi Nakanishi
5. P. Richardson
6. T. Hideshima
7. A. Goy
8. P. Wen

Citations in the corpus

• Targeting Apoptosis Pathways in Cancer Therapy (2005, background): “Based on its promising preclinical data and clinical activity in Phase I studies in myeloma, a Phase II multicenter trial in refractory and relapsed multiple myeloma patients was performed.(100) Bortezomib was given at a dose of 1.”
• Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. (2006, neutral): “Peripheral neuropathy 8 (1) 15 (2) 68 (7) .”
• Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. (2006, result): “The safety profile of bortezomib was predictable and manageable, and similar to that in relapsed or refractory MM.(50-52) The incidence of peripheral neuropathy was higher compared with the Assessment of Proteasome Inhibition for Extending Remissions phase III study in MM,(51) perhaps due to inheren”
• The proteasome: a suitable antineoplastic target (2004, positive): “A tolerable and efficacious dose and schedule of bortezomib in myeloma was defined in Phase I and II studies ( Table 3”
• Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. (2006, methodology): “The eligibility criteria for the patients enrolled onto SUMMIT and CREST have been described previously.(1,2) Eligible patients had relapsed and/or refractory myeloma; patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (POEMS) were excluded, ”
• Improved survival in multiple myeloma and the impact of novel therapies. (2008, background): “There were 245 males (63%); median (range) age at transplantation was 57 years (33-75), and the median time to transplantation was 8 months (1-90 months) from diagnosis.”
• Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. (2011, background): “LINES OF THERAPY A line of therapy is defined as one or more cycles of a planned treatment program.(4) This”
• Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. (2007, background): “Inactivation of TRAF3 is associated with poor response to dexamethasone and a good response to proteasome inhibitors Proteasome inhibitors are a novel class of anti-cancer agents with remarkable clinical activity in MM (Richardson et al., 2003).”